Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: Efficacy, anatomical outcomes and safety

Hyun Goo Kang, Eun Young Choi, Suk Ho Byeon, Sung Soo Kim, Hyoung Jun Koh, Sung Chul Lee, Min Kim

Research output: Contribution to journalArticle

Abstract

Background/Aims To compare the efficacy, anatomical outcomes and complications of intravitreal ranibizumab with those of laser photocoagulation for retinopathy of prematurity (ROP). Methods This is a retrospective case series of 314 eyes from 165 infants diagnosed with type I ROP and treated with either laser photocoagulation (161 eyes) or intravitreal ranibizumab (0.25 mg/0.025 mL) injection (153 eyes) between January 2006 and December 2016 in a tertiary referral-based hospital. The main outcome was the rate of recurrence requiring additional treatment. Secondary outcomes included the incidence of major complications and final refractive error. Results The mean follow-up was 36.3±31.9 months. Recurrences requiring further intervention were noted in 22 (13.7%) laser-treated and 15 (9.8%) ranibizumab-treated eyes (p=0.196). Retinal detachment (8 vs 1, p=0.037) and macular dragging (7 vs 1, p=0.039) were observed in the laser-treated and injection-treated groups, respectively, but no systemic or neurodevelopmental adverse events were reported. In the ranibizumab group, 95.6% showed fully vascularised retinas. Multivariate analyses revealed that birth weight (OR 0.993, p=0.023) and higher ROP stage (OR 11.222, p=0.008) influenced the incidence of major complications. Conclusion Intravitreal ranibizumab for ROP appears to achieve similar therapeutic effects than did laser photocoagulation, but with fewer surgical complications such as retinal detachment or macular dragging.

Original languageEnglish
Pages (from-to)1332-1336
Number of pages5
JournalBritish Journal of Ophthalmology
Volume103
Issue number9
DOIs
Publication statusPublished - 2019 Sep 1

Fingerprint

Retinopathy of Prematurity
Light Coagulation
Lasers
Safety
Retinal Detachment
Recurrence
Injections
Refractive Errors
Incidence
Therapeutic Uses
Tertiary Care Centers
Birth Weight
Retina
Multivariate Analysis
Ranibizumab

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Kang, Hyun Goo ; Choi, Eun Young ; Byeon, Suk Ho ; Kim, Sung Soo ; Koh, Hyoung Jun ; Lee, Sung Chul ; Kim, Min. / Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity : Efficacy, anatomical outcomes and safety. In: British Journal of Ophthalmology. 2019 ; Vol. 103, No. 9. pp. 1332-1336.
@article{f4cc29430f8146679ed0fbb02db0919f,
title = "Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: Efficacy, anatomical outcomes and safety",
abstract = "Background/Aims To compare the efficacy, anatomical outcomes and complications of intravitreal ranibizumab with those of laser photocoagulation for retinopathy of prematurity (ROP). Methods This is a retrospective case series of 314 eyes from 165 infants diagnosed with type I ROP and treated with either laser photocoagulation (161 eyes) or intravitreal ranibizumab (0.25 mg/0.025 mL) injection (153 eyes) between January 2006 and December 2016 in a tertiary referral-based hospital. The main outcome was the rate of recurrence requiring additional treatment. Secondary outcomes included the incidence of major complications and final refractive error. Results The mean follow-up was 36.3±31.9 months. Recurrences requiring further intervention were noted in 22 (13.7{\%}) laser-treated and 15 (9.8{\%}) ranibizumab-treated eyes (p=0.196). Retinal detachment (8 vs 1, p=0.037) and macular dragging (7 vs 1, p=0.039) were observed in the laser-treated and injection-treated groups, respectively, but no systemic or neurodevelopmental adverse events were reported. In the ranibizumab group, 95.6{\%} showed fully vascularised retinas. Multivariate analyses revealed that birth weight (OR 0.993, p=0.023) and higher ROP stage (OR 11.222, p=0.008) influenced the incidence of major complications. Conclusion Intravitreal ranibizumab for ROP appears to achieve similar therapeutic effects than did laser photocoagulation, but with fewer surgical complications such as retinal detachment or macular dragging.",
author = "Kang, {Hyun Goo} and Choi, {Eun Young} and Byeon, {Suk Ho} and Kim, {Sung Soo} and Koh, {Hyoung Jun} and Lee, {Sung Chul} and Min Kim",
year = "2019",
month = "9",
day = "1",
doi = "10.1136/bjophthalmol-2018-312272",
language = "English",
volume = "103",
pages = "1332--1336",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "9",

}

Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity : Efficacy, anatomical outcomes and safety. / Kang, Hyun Goo; Choi, Eun Young; Byeon, Suk Ho; Kim, Sung Soo; Koh, Hyoung Jun; Lee, Sung Chul; Kim, Min.

In: British Journal of Ophthalmology, Vol. 103, No. 9, 01.09.2019, p. 1332-1336.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity

T2 - Efficacy, anatomical outcomes and safety

AU - Kang, Hyun Goo

AU - Choi, Eun Young

AU - Byeon, Suk Ho

AU - Kim, Sung Soo

AU - Koh, Hyoung Jun

AU - Lee, Sung Chul

AU - Kim, Min

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Background/Aims To compare the efficacy, anatomical outcomes and complications of intravitreal ranibizumab with those of laser photocoagulation for retinopathy of prematurity (ROP). Methods This is a retrospective case series of 314 eyes from 165 infants diagnosed with type I ROP and treated with either laser photocoagulation (161 eyes) or intravitreal ranibizumab (0.25 mg/0.025 mL) injection (153 eyes) between January 2006 and December 2016 in a tertiary referral-based hospital. The main outcome was the rate of recurrence requiring additional treatment. Secondary outcomes included the incidence of major complications and final refractive error. Results The mean follow-up was 36.3±31.9 months. Recurrences requiring further intervention were noted in 22 (13.7%) laser-treated and 15 (9.8%) ranibizumab-treated eyes (p=0.196). Retinal detachment (8 vs 1, p=0.037) and macular dragging (7 vs 1, p=0.039) were observed in the laser-treated and injection-treated groups, respectively, but no systemic or neurodevelopmental adverse events were reported. In the ranibizumab group, 95.6% showed fully vascularised retinas. Multivariate analyses revealed that birth weight (OR 0.993, p=0.023) and higher ROP stage (OR 11.222, p=0.008) influenced the incidence of major complications. Conclusion Intravitreal ranibizumab for ROP appears to achieve similar therapeutic effects than did laser photocoagulation, but with fewer surgical complications such as retinal detachment or macular dragging.

AB - Background/Aims To compare the efficacy, anatomical outcomes and complications of intravitreal ranibizumab with those of laser photocoagulation for retinopathy of prematurity (ROP). Methods This is a retrospective case series of 314 eyes from 165 infants diagnosed with type I ROP and treated with either laser photocoagulation (161 eyes) or intravitreal ranibizumab (0.25 mg/0.025 mL) injection (153 eyes) between January 2006 and December 2016 in a tertiary referral-based hospital. The main outcome was the rate of recurrence requiring additional treatment. Secondary outcomes included the incidence of major complications and final refractive error. Results The mean follow-up was 36.3±31.9 months. Recurrences requiring further intervention were noted in 22 (13.7%) laser-treated and 15 (9.8%) ranibizumab-treated eyes (p=0.196). Retinal detachment (8 vs 1, p=0.037) and macular dragging (7 vs 1, p=0.039) were observed in the laser-treated and injection-treated groups, respectively, but no systemic or neurodevelopmental adverse events were reported. In the ranibizumab group, 95.6% showed fully vascularised retinas. Multivariate analyses revealed that birth weight (OR 0.993, p=0.023) and higher ROP stage (OR 11.222, p=0.008) influenced the incidence of major complications. Conclusion Intravitreal ranibizumab for ROP appears to achieve similar therapeutic effects than did laser photocoagulation, but with fewer surgical complications such as retinal detachment or macular dragging.

UR - http://www.scopus.com/inward/record.url?scp=85058101707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058101707&partnerID=8YFLogxK

U2 - 10.1136/bjophthalmol-2018-312272

DO - 10.1136/bjophthalmol-2018-312272

M3 - Article

C2 - 30514709

AN - SCOPUS:85058101707

VL - 103

SP - 1332

EP - 1336

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 9

ER -